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Abstract SUCLA2 encodes the ATP-forming b subunit
(A-SUCL-b) of succinyl-CoA ligase, an enzyme of the
citric acid cycle. Mutations in SUCLA2 lead to a mito-
chondrial disorder manifesting as encephalomyopathy with
dystonia, deafness and lesions in the basal ganglia. Despite
the distinct brain pathology associated with SUCLA2
mutations, the precise localization of SUCLA2 protein has
never been investigated. Here, we show that immunore-
activity of A-SUCL-b in surgical human cortical tissue
samples was present exclusively in neurons, identified by
their morphology and visualized by double labeling with a
fluorescent Nissl dye. A-SUCL-b immunoreactivity co-
localized [99 % with that of the d subunit of the mito-
chondrial F0–F1 ATP synthase. Specificity of the anti-A-
SUCL-b antiserum was verified by the absence of labeling
in fibroblasts from a patient with a complete deletion of
SUCLA2. A-SUCL-b immunoreactivity was absent in glial
cells, identified by antibodies directed against the glial
markers GFAP and S100. Furthermore, in situ hybridiza-
tion histochemistry demonstrated that SUCLA2 mRNA was
present in Nissl-labeled neurons but not glial cells labeled
with S100. Immunoreactivity of the GTP-forming b sub-
unit (G-SUCL-b) encoded by SUCLG2, or in situ hybrid-
ization histochemistry for SUCLG2 mRNA could not be
demonstrated in either neurons or astrocytes. Western
blotting of post mortem brain samples revealed minor
G-SUCL-b immunoreactivity that was, however, not
upregulated in samples obtained from diabetic versus non-
diabetic patients, as has been described for murine brain.
Our work establishes that SUCLA2 is expressed exclu-
sively in neurons in the human cerebral cortex.
Keywords Succinate thiokinase 
Succinyl coenzyme A synthetase  Substrate-level
phosphorylation  mtDNA  Neuronal mitochondrial
marker
Introduction
Succinyl-CoA ligase [(SUCL), also known as succinyl
coenzyme A synthetase (SCS), or succinate thiokinase
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(STK)] is a heterodimeric enzyme, composed of an
invariant a subunit encoded by SUCLG1 and a substrate-
specific b subunit, encoded by either SUCLA2 or SUCLG2.
This dimer combination results in either an ATP-forming
(EC 6.2.1.5) or a GTP-forming SUCL (EC 6.2.1.4). The
enzyme is located in the mitochondrial matrix being part of
the citric acid cycle, catalyzing the conversion of succinyl-
CoA and ADP (or GDP) to CoASH, succinate and ATP (or
GTP) (Johnson et al. 1998). DG for this reaction is 0.07 kJ/
mol and therefore it is reversible (Li et al. 2013). When
SUCL proceeds in the direction towards succinyl-CoA, this
product may follow heme- or ketone body metabolism
(Labbe et al. 1965; Ottaway et al. 1981). On the other hand,
the reaction proceeding towards ATP or GTP formation is
termed ‘substrate-level phosphorylation’ and can occur in
the absence of oxygen. Substrate-level phosphorylation
during anoxia/ischemia rescues cells from cytosolic ATP
depletion (Chinopoulos et al. 2010, 2013; Kiss et al. 2013).
GTP is a central regulator of cellular anabolism (Pall
1985); in mitochondria, GTP is used by the protein syn-
thesis machinery, the PEP carboxykinase isoform 2 and
GTP-AMP phosphotransferase and other GTP-binding
proteins (Thomson 1998). GTP salvage inside the matrix is
critical because it is believed not to be transported through
the inner mitochondrial membrane in higher organisms
(Pfaff et al. 1965). However, guanine nucleotide transport
by atractyloside-sensitive and -insensitive mechanisms in
isolated heart mitochondria has been reported by one group
(McKee et al. 1999, 2000), but the carrier has not been
found. On the other hand, it is well established that yeasts
harbor a mitochondrial GTP/GDP translocase, but a
homologue in higher organisms has not been identified
(Vozza et al. 2004); accordingly, yeasts lack a GTP-
forming SUCL (Przybyla-Zawislak et al. 1998). GTP-
forming SUCL may support ATP formation in the matrix
through the concerted action with a mitochondrial isoform
of a nucleotide diphosphate kinase known as nm23-H4; this
kinase complexes with either ATP- or GTP-forming SUCL
(Kadrmas et al. 1991; Kowluru et al. 2002).
Considering the extensive involvement of SUCL in
vital biochemical pathways, it is not surprising that its
deficiency leads to serious pathology. The disease phe-
notype matches the tissue-specific expression of its sub-
units: A-SUCL-b is highly expressed in skeletal muscle,
brain and heart, while G-SUCL-b is barely detected in
brain and muscle, but strongly expressed in liver and
kidney (Lambeth et al. 2004). Accordingly, mutations in
SUCLA2 (MIM ID #612073) results in Leigh’s or a
Leigh-like syndrome with onset of severe hypotonia in
early childhood, muscular atrophy and sensorineural
hearing impairment often leading to death during child-
hood. Neuroimaging findings include basal ganglia
involvement, especially affecting the putamen and the
caudate nuclei (Carrozzo et al. 2007), demyelination and
atrophy (Ostergaard et al. 2007b). SUCLA2 deficient
patients show no abnormalities related to liver functions.
Mutations in the a subunit-encoding SUCLG1 gene have
been reported in 16 patients (Ostergaard et al. 2007a,
2010) and they are associated with a phenotype similar to
that seen in patients with SUCLA2 deficiency, or a fatal
infantile lactic acidosis. Mutations in the SUCLG2 gene
have not been reported so far, and may be incompatible
with life.
SUCL deficiency is associated with mtDNA depletion,
characterized by a massive reduction of mitochondrial
DNA content. Three main clinical presentations of mtDNA
depletion syndrome (MDS) are known: (a) myopathic,
(b) encephalomyopathic and (c) hepatocerebral, depending
on the tissues affected and their residual mitochondrial
DNA levels (Rotig and Poulton 2009). SUCLA2 deficiency
is associated with the encephalomyopathic tier. mtDNA
depletion (15–40 % residual amount) was found in the
muscle samples of such patients (Ostergaard 2008). How-
ever, mtDNA depletion was found in fibroblasts from
patients with SUCLA2 deficiencies of only two out of four
patients in one study (Carrozzo et al. 2007), while in
(Miller et al. 2011) mtDNA depletion was evident only
after serum deprivation which could be ameliorated by
supplementation of deoxyribonucleosides. Data on brain
biopsies from SUCLA2 deficiency patients are not avail-
able. In the most comprehensive study in terms of exten-
sive biopsies from patients with MDS, samples were
collected from muscle, liver, blood or fibroblasts, but not
brain (Navarro-Sastre et al. 2012). Yet, in SUCLA2 defi-
ciency it is the brain that seems to be the most vulnerable
tissue, as SUCLG2 and nm23-H4 are only weakly expres-
sed (Milon et al. 1997; Lambeth et al. 2004). SUCL forms
a physical complex with nm23-H4, the lack of which
hinders the kinase function leading to a defect in the last
step of the mitochondrial nucleotide salvage pathway (El-
peleg et al. 2005), thus causing mtDNA depletion
(Ostergaard et al. 2007a, 2010)
Fibroblasts and skeletal muscle are homogeneous tissues
(despite the different categories of muscle fiber types);
however, the brain consists of several different cell types,
the major categories being neurons and glial cells. There is
an obvious gap of knowledge regarding the pathophysiol-
ogy of SUCLA2 deficiency in the brain, the organ that
suffers the most from this inborn error of metabolism.
Analysis of expression of SUCLA2 in the human brain has
been reported only once, but in that report cell- or region-
specific expression was not investigated (Lambeth et al.
2004). In this study, we show unequivocally that SUCLA2
is expressed exclusively in the neurons of the human brain.
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Results
The specificity of SUCLA2 and SUCLG2
immunoreactivity in human tissues
The specificity of SUCLA2 immunoreactivity was validated
using human fibroblasts from a control subject versus those
from a patient suffering from a complete deletion in SUCLA2
gene. The specificity of SUCLG2 immunoreactivity was
validated using HEK293 cells, see Fig. 1. The mitochondrial
network was selectively stained by loading cells with Mito-
tracker Orange (MTO, 1 lM, red) prior to fixation, see panels
A2 (control fibroblasts), B2 (SUCLA2-deficient fibroblasts)
and C2 (HEK293 cells). Normal human fibroblasts were
strongly labeled with the procedure of SUCLA2 immuno-
staining (panel A1, green), and there was a robust co-locali-
zation with the decoration obtained by MTO (panel A3,
yellow). In contrast, fibroblasts derived from the patient
lacking SUCLA2 did not show SUCLA2 immunolabeling
(panel B1), while the mitochondrial network outlined by MTO
was unremarkable (panel B2, red), and accordingly there was
no SUCLA2 immunoreactivity-MTO co-localization (panel
B3). For validating the antibody raised against SUCLG2 we
immunolabeled HEK293 cells which exhibit a very high
expression of this protein (Tanner et al. 2007); confocal
images of G-SUCL-b immunolabeling in these cells are
shown in panel C1 (green). MTO labeling was intense (panel
C2, red), and the extent of co-localization was also evident,
shown in panel C3 (yellow). The scale bar is 20 lm.
SUCLA2 immunoreactivity and absence of SUCLG2
immunoreactivity in the human frontal and temporal
cortical samples
SUCLA2 antibody labeled a large number of cells in both the
frontal and temporal cortex with no visible difference between
the male and female human brain (Fig. 2a). The labeled cells
were numerous in all layers of the cortices except layer I. The
labeled cells demonstrated different morphologies. A number
of large pyramidal cells were labeled but smaller cells also
showed SUCLA2 immunoreactivity. In general, SUCLA2
immunoreactivity was present within the cell bodies as well as
the proximal dendrites but not in the nuclei (Fig. 2a, b). The
same procedure but for SUCLG2 immunoreactivity applied
for HEK293 cells or using more concentrated or more diluted
antiserum resulted in no specific cellular labeling in the human
frontal and temporal cortical samples (Fig. 2c), in accordance
with the original report by the group of Lambeth (Lambeth
et al. 2004). It is to be noted that SUCLG2 for humans exhibits
transcript variants. However, all transcripts are identical in the
region 1–396, except in position 220 (see supplemental
Fig. 1). The antibody that we used to identify SUCLG2
(Abcam, Cat. No. #ab96172) was raised by immunizing
rabbits with a recombinant fragment corresponding to a region
within the N terminal amino acids 1–204 of human SUCLG2.
Therefore, it should not be able to distinguish among transcript
variants.
The mitochondrial localization of SUCLA2
immunoreactivity
The labeling of SUCLA2 within the neurons is punctate
with a cellular localization resembling that of mitochon-
dria, suggesting the presence of SUCLA2 immunoreactiv-
ity in this organelle (Fig. 3a1, b1). Although in situ
mitochondria are normally filamentous, cellular stress as it
may be the case during handling of the specimen or simply
postmortem delay will cause mitochondrial fragmentation,
yielding a punctate appearance. To identify the mitochon-
drial presence of SUCLA2, co-localization studies were
performed for F0–F1 ATP synthase subunit d. The distri-
bution of F0–F1 ATP synthase subunit d delineated the
expected distribution of mitochondria (Fig. 3a2, b2). Fur-
thermore, an almost complete co-localization of SUCLA2
and F0–F1 ATP synthase subunit d and the absence of
singly labeled structures indicate the exclusively mito-
chondrial localization of SUCLA2 (Fig. 3a3, b3).
Identification of cell types containing SUCLA2
immunoreactivity in the human temporal cortex
The distribution of SUCLA2-immunoreactive cells is simi-
lar to that of neurons: they are present in all layers of the
temporal cortex but their density is small in layer I (Fig. 4a1,
b1). SUCLA2 immunoreactivity was present in 88 % of cells
identified as neuron based on its larger, less irregular shape in
Nissl staining (Fig. 4a2). In contrast, dark Nissl-labeled
cells, possibly glial cells do not contain SUCLA2 at all
(Fig. 4a2). Unfortunately, labeling with NeuN (clone BBS/
NC/VI-H14) or neuron-specific enolase used for the immu-
nocytochemical identification of neurons did not label our
human brain sections consistently to confirm the neuronal
location of SUCLA2 immunoreactivity. Instead, we used
glial markers to confirm the absence of SUCLA2 immuno-
reactivity in these cell types. Indeed, a lack of co-localization
of SUCLA2 and S100, an astrocyte marker suggested that
SUCLA2 was absent in astrocytes (Fig. 4b1, b2, b3). In
addition, the glial marker GFAP also showed a different
distribution from SUCLA2 immunoreactive cells and did not
co-localize with SUCLA2 immunoreactivity (Fig. 5).
The presence of SUCLA2 but not SUCLG2 mRNA
in the human temporal cortex
A single band appeared on gels following RT-PCR using all
primer pairs specific to SUCLA2 and SUCLG2 when cDNA
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from human fibroblasts were used (Fig. 6a). However, when
human temporal cortical cDNA was used, the same molec-
ular weight products appeared only with SUCLA2 primers
albeit with a smaller bandwidth. In contrast, SUCLG2
primers produced extremely faint bands. It must be noted that
a cDNA clone containing a complete ORF for SUCLG2
obtained from the human hippocampus appears in the liter-
ature (Strausberg et al. 2002). In our RT-PCR experiments
very weak signals may well originate from SUCLG2 mRNA
of lymphocytes, endothelial cells or pericytes of vessels
present in the specimen. The lengths of the PCR products
were consistent with the lengths calculated from the position
of the corresponding primer pair (Fig. 6a). PCR reactions
without cDNA template were always included, and we did
not detect bands in these negative controls (not shown).
The distribution of mRNA expression of SUCLA2
in the human temporal cortex
In situ hybridization histochemistry revealed the distribu-
tion of mRNA of SUCLA2 (Fig. 6b), whereas that of
SUCLG2 was not detected in the human temporal cortex
Fig. 1 Co-immunolabeling of human fibroblasts (SUCLA2) and
HEK293 cells (SUCLG2) with Mitotracker Orange (MTO). a1
SUCLA2 immunoreactivity in normal human fibroblasts. Intracellular
structures resembling mitochondria are intensely labeled. a2 MTO
labeling outlining the mitochondrial network in normal human
fibroblasts. a3 Merged image of SUCLA2 immunodecoration with
MTO labeling. b1 Specific labeling for SUCLA2 is absent in fibroblasts
derived from the patient lacking SUCLA2. b2 MTO staining outlining
the mitochondrial network in the fibroblasts obtained from the patient
lacking SUCLA2. b3 Merged image of SUCLA2 immunodecoration
with MTO labeling, revealing lack of co-localization. c1 SUCLG2
labels HEK293 cells. c2 MTO labeling outlining the mitochondrial
network in HEK293 cells. c3 Merged image of SUCLG2 immunodec-
oration with MTO labeling in HEK293 cells. Scale bar 20 lm
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(Fig. 6c), in agreement with the immunohistochemistry and
RT-PCR results shown above, and the earlier results by the
group of Lambeth (Lambeth et al. 2004). This result also
verifies that the absence of G-SUCL-b immunoreactivity is
genuine, and does not reflect a technical limitation of the
antibody in our immunohistochemistry and/or Western
blotting protocols. The two antisense probes for SUCLA2
resulted in identical hybridization patterns; therefore, they
will not be separately described. In the temporal cortex, all
layers contained SUCLA2 mRNA, whereas the corpus
callosum (cc) did not show any labeling. The intensity of
labeling was the highest in the pyramidal layers containing
large pyramidal cells (Fig. 6b). The intensity of labeling
was lower in layer VI and in the superficial layers. In
particular, layer I contained only a small number of cells
expressing SUCLA2. In the human temporal cortical brain
sections labeled for SUCLA2 mRNA, Nissl-labeled cells as
well as S100-immunoreactive cells were present. The dis-
tribution of Nissl-labeled neurons (Fig. 7a) was similar to
that of SUCLA2-expressing cells, whereas S100-immuno-
reactive glial cells had a more even distribution pattern
(Fig. 7b). Furthermore, high-magnification pictures indi-
cated that over 90 % of Nissl-labeled neurons exhibited
SUCLA2 mRNA (Fig. 7c) while 95 % of SUCLA2 mRNA-
expressing cells were identified as neurons based on Nissl
labeling in the human temporal cortex. In contrast, the
distribution of SUCLA2 mRNA-expressing cells was dif-
ferent from that of S100-immunoreactive cells in high-
magnification pictures (Fig. 7d) and SUCLA2 mRNA-
expressing cells showed less than 5 % co-localization with
S100 immunoreactivity.
SUCLA2 and SUCLG2 immunoreactivities
in homogenates from various brain regions
The antibody directed against SUCLA2 worked in immu-
nohistochemistry protocols only from fresh human brain
specimens. However, the antibody recognized reliably
SUCLA2 in samples that have been preserved in our Brain
Tissue Bank for prolonged periods of time which were
processed for Western blotting. This provided the oppor-
tunity to examine the presence of SUCLA2 from several
brain regions. As shown in Fig. 8 panel A, homogenate
samples obtained from three different donors (Table 1a, b)
from temporal cortex, caudate nucleus, putamen, frontal
cortex, white matter and cerebellar cortex tested positive
for SUCLA2 immunoreactivity. Even though white matter
does not contain neuronal cell bodies it still exhibited
significant SUCLA2 immunoreactivity, probably originat-
ing from the mitochondria found along the axons. ‘MB’
signifies mouse brain homogenates from four different
animals (numbered as 1, 2, 3 and 4). In this and the other
panels of Fig. 8, b-actin immunoreactivity served as a
loading control for all lanes.
The specificity of the SUCLA2 antibody is certified by
the blot shown in panel B, where there was no immuno-
reactivity from fibroblasts of a patient suffering from
complete deletion of the SUCLA2 gene.
SUCLG2 immunoreactivity (panel A) was extremely
weak in the human brain samples, as compared to the
mouse brain samples, in accordance with the results of
previous Western blot experiments (Kiss et al. 2013). As
for the case of RT-PCR results, such weak SUCLG2
Fig. 2 Immunolabeling for SUCLA2 but not SUCLG2 in the human
temporal cortex. a SUCLA2-immunoreactive cells with DAB visu-
alization are evenly distributed in layer V of the human temporal
cortex. b A large magnification picture demonstrates distribution of
SUCLA2 immunoreactivity that resembles to that of mitochondria
within a labeled cell. c SUCLG2 immunoreactivity is absent in the
human temporal cortex. Scale bars 50 lm for a and c, and 10 lm for
b
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immunoreactivity in human brain homogenates may orig-
inate from trapped lymphocytes, endothelial cells or peri-
cytes from vessels present in the specimen, and not being
genuine to neurons or glial cells. Although there are no
tissues available with null expression of SUCLG2 (as in the
case for the fibroblasts from the patient suffering from
complete deletion of the SUCLA2 gene), the fact that the
bands obtained from mouse tissues and the human speci-
mens appeared at the exact same molecular weight affords
a reasonable degree of assurance that SUCLG2 immuno-
reactivity is indeed genuine.
In the rat brain, streptozotocin-induced diabetes upreg-
ulates GTP-forming succinyl-CoA ligase activity more
than ten times (Jenkins and Weitzman 1986). Mindful of
Fig. 3 The mitochondrial
localization of SUCLA2 based
on its co-localization with the d
subunit of the F0–F1 ATP
synthase. a1 SUCLA2
immunoreactivity in the human
temporal cortex visualized by
FITC-tyramide amplification
immunofluorescence. Red blood
cells in some capillaries are
labeled because of their
endogenous peroxidase activity.
b1 A high-magnification
confocal image demonstrates
the localization of SUCLA2
within a SUCLA2-positive cell.
a2 Distribution of the
immunoreactivity of the
mitochondrial marker F0–F1
ATP synthase subunit d in the
same field as a1. b2 F0–F1 ATP
synthase subunit d
immunoreactivity in the same
field as B1. a3 Yellow color
indicates co-localization of
SUCLA2 and F0–F1 ATP
synthase subunit d. An almost
complete absence of singly
labeled structures can be
observed except for the red
blood cells. b3 The co-
localization of SUCLA2 and
F0–F1 ATP synthase subunit d is
predominant even within a cell
at high magnification. Scale
bars 50 lm for a1–a3 and
20 lm for b1–b3
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this, and assuming that diabetes may upregulate SUCLG2
expression in the human brain, we compared SUCLG2
(and SUCLA2) immunoreactivity in brain tissue homoge-
nates from four controls versus four patients that suffered
from diabetes mellitus for several years (Table 1c, d) The
results are shown in panel C of Fig. 8: SUCLG2 immu-
noreactivity was not increased in the samples from the
diabetic patients as compared to those from control sub-
jects, also verified by densitometric analysis of the bands
(not shown). This result affords further credibility to the
claim that SUCLG2 is not expressed in the human brain to
a significant extent.
Discussion
Here, we have investigated the cell-specific expression of
SUCLA2 and SUCLG2 in the human brain. The most
important observation was that A-SUCL-b was present
Fig. 4 The neuronal
localization of SUCLA2
immunoreactivity in the human
temporal cortex. a1 The
distribution of SUCLA2-
positive cells is similar to that of
Nissl-labeled cells (red), both
present throughout the temporal
cortex. a2 A higher
magnification image reveals that
essentially all large Nissl-
labeled cells with irregular
shape demonstrate SUCLA2
immunolabeling (yellow cells).
In contrast, small, intensely
labeled round-shape cells do not
exhibit SUCLA2
immunoreactivity and remain
red (arrowheads). Some blood
vessels are labeled green
because of the peroxidase
activity of the red blood cells
present in the vessels in the non-
perfused human tissue. a3 A
high-magnification confocal
microscopy image
demonstrating the punctuate
location of SUCLA2
immunoreactivity within the
cytosol of Nissl-labeled neurons
whereas small glial cells do not
exhibit SUCLA2
immunoreactivity. b1 The
distribution of the glial marker
S100 (red) is different from that
of SUCLA2-positive cells
(green). b2 A higher
magnification image
demonstrates lack of co-
localization between SUCLA2
and S100. Glial cells labeled
with S100 are indicated by
arrowheads. b3 High-
magnification confocal picture
shows that SUCLA2 and S100
are located in different cell
types. Scale bars 200 lm for
a1, 50 lm for a2, 20 lm for a3,
500 lm for b1, 50 lm for b2,
and 20 lm for b3
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exclusively in neurons, and not in other cell types. An
obvious pathophysiological implication for astrocytes
lacking A-SUCL-b and therefore being incapable of ATP
provision by matrix substrate-level phosphorylation, is that
their mitochondria are more likely to engage in cytosolic
ATP consumption (Chinopoulos et al. 2010) than neuronal
mitochondria, during natural fluctuations of their mem-
brane potentials (Gerencser et al. 2012). As an extension of
this, astrocytic mitochondria should be more vulnerable
than neuronal mitochondria in terms of relying on—in
house—ATP reserves during energy crisis, such as during
brain ischemia (Chinopoulos and Adam-Vizi 2010; Chi-
nopoulos 2011a, b). To this end, the weak expression of
nm23-H4 (Milon et al. 1997), together with the lack of
G-SUCL-b expression in astrocytes preclude the possibil-
ity of matrix ATP formation through GTP
transphosphorylation.
Furthermore, the notion that both ATP- and GTP-
forming SUCL activity should exhibit an extremely low—
if any—rate in human astrocytes, hints at peculiarities of
the directionality of citric acid cycle in these cells (Chi-
nopoulos 2013). Although the citric acid cycle is branded
as a ‘‘cycle’’, it does not necessarily operate as one (Chi-
nopoulos 2013). It is well known, that astrocytes produce
and release large quantities of succinate (Westergaard et al.
1994). Succinate can be the end-product of a ‘backflux’
citric acid cycle (Brekke et al. 2012), commencing from
pyruvate that is converted to oxaloacetate by pyruvate
carboxylase. Pyruvate carboxylase is mostly expressed in
liver and kidneys being part of gluconeogenesis, but it is
also found in the astrocytes of the brain (Shank et al. 1985;
Yu et al. 1983), playing an important role in lipogenesis
and synthesis of neurotransmitters (Wallace et al. 1998;
Sonnewald and Rae 2010).
Another relevant concept to our findings is that GABA
uptake in the neuropil occurs through the GABA trans-
porter GAT-3, which is exclusively expressed in astrocytes
(Minelli et al. 1996), as well as GAT-1 and -2, which are
found both in astrocytic processes and other neuronal- and
non-neuronal elements (Conti et al. 1998, 1999). GABA
metabolism in the astrocytes proceeds through GABA
transaminase (which also requires a-ketoglutarate) yielding
succinate semialdehyde (and glutamate) that is in turn
processed by succinate semialdehyde dehydrogenase
yielding succinate which enters the citric acid cycle, thus
effectively by-passing the ‘missing’ SUCL, since neither
SUCLA2 nor SUCLG2 is expressed in these cells.
Finally, in the absence of either ATP- or GTP-forming
SUCL, succinyl-CoA emerging from the a-ketoglutarate
dehydrogenase complex in astrocytic mitochondria could
be further processed towards heme and/or ketone body
metabolism, pathways which are fully operational in
astrocytes (Lopes-Cardozo et al. 1986; Dringen et al.
2007), or serve as cofactor for lysine succinylation (Zhang
et al. 2011), a wide-spread post-translational modification;
this would also prevent a ‘coenzyme A trap’ in the form of
succinyl-CoA.
In aggregate, our findings presented in this paper have
strong physiological implications regarding the differential
metabolism of neurons versus astrocytes in the human
brain and pathological implications related to the impact of
SUCLA2 deficiency on brain functions. Furthermore, our
study pinpoints SUCLA2 as a reliable marker for neuronal
mitochondria. By the same token, any report on the func-
tion or activity of ATP-forming SUCL in brain tissue
should not apply for the whole brain, only for neurons.
Finally, and in the same line, intracellular pathological
manifestations of the brain caused by SUCLA2 deficiency,
such as mtDNA depletion, should only be sought in
neurons.
Materials and methods
Human brains
Human brain samples were collected in accordance with
the Ethical Rules for Using Human Tissues for Medical
Research in Hungary (HM 34/1999) and the Code of Ethics
of the World Medical Association (Declaration of
Fig. 5 The different cellular localization of SUCLA2 and GFAP.
SUCLA2 labels a number of evenly distributed cells with punctuate
appearance (red). GFAP-positive glial cells (green) possessing the
characteristic glial processes are also evenly distributed. These glial
cells, however, are not labeled by SUCLA2 whereas SUCLA2 cells
are not labeled by GFAP. Scale bar 100 lm
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Helsinki). Post mortem tissue samples were taken during
brain autopsy. In addition, surgical brain samples were
obtained from tissue removed during brain surgeries at the
Department of Neurosurgery Medical School, University
of Pe´cs in the framework of the Human Brain Tissue Bank,
Budapest. For autopsy, brains were removed from the skull
with a post mortem delay of 2–6 h. Prior written informed
consent was obtained from the patients or from the next of
kin for autopsies, which included the request to conduct
neurochemical analyses. The protocols including analyses
of tissue samples were approved by institutional ethics
committee of the Semmelweis University and the Univer-
sity of Pe´cs. The three surgical patients underwent the
removal of brain tumors. The 11 subjects, whose brains
were used in the autopsy study died without any known
neurological or affective disorder. The medical history of
the subjects was obtained from medical or hospital records,
interviews with family members and relatives, as well as
from pathological and neuropathological reports. All per-
sonal identifiers had been removed and samples were
coded before the analyses of tissue.
Surgically dissected freshly frozen temporal cortical sam-
ples from a 66-year-old woman were used for RT-PCR and the
development of in situ hybridization probes. In situ hybrid-
ization histochemistry was performed in temporal cortical
samples from this patient as well as in the temporal cortex
from a 64-year-old woman. Immunolabeling was performed
using frontal cortical sample of a 58-year-old man and tem-
poral cortical samples from the 64-year-old and the 66-year-
old woman; tissue blocks of the latter two patients were also
used for in situ hybridization histochemistry. Surgical samples
that underwent immediate freezing for situ hybridization
Fig. 6 a An RT-PCR experiment demonstrates the expression of
SUCLA2 but not SUCLG2 mRNA in the human temporal cortex by
showing PCR products run on gel. The appearance of appropriate
bands on the gel for primer pairs A–C for SUCLA2 (235, 309, and
242 bp, respectively) and primer pairs A–D for SUCLG2 (279, 387,
366, and 211 bp, respectively) in human fibroblasts indicate SUCLA2
and SUCLG2 expression in this cell type. In contrast, when the
template of the PCR reaction was cDNA prepared from freshly
dissected surgical human temporal cortex samples, only SUCLA2 but
not SUCLG2 resulted in visible bands. Dark-field photomicrographs
of human temporal cortex labeled with in situ hybridization
histochemistry for SUCLA2 (b), and SUCLG2 (c). The white dots
represent labeled cells. All cortical layers but not the corpus callosum
(cc) is labeled for SUCLA2 (b). The intensity of labeling is highest in
layers III–V whereas layers I, II, and VI contains less intensely
labeled cells. In contrast, SUCLG2 labeling above the background is
absent in all layers of the cerebral cortex (c). Scale bar 1 mm
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histochemistry or immediate fixation for immunolabeling
were used in histochemical techniques, because they provided
markedly superior results for visualizing SUCLA2 expression
and distribution as compared to post mortem samples.
For western blotting, autopsy samples from different
brain regions of 11 subjects were obtained by microdis-
section. Individual brain nuclei were microdissected from
postmortem brains (that have been rapidly frozen on dry
ice and stored at -80 C) using the micropunch technique
(Palkovits 1973). Briefly, brains were cut as 1.0-1.5 mm
thick coronal sections, and individual brain regions and
nuclei were removed by special punch needles with an
inside diameter of 1.0–3.5 mm, using either a head mag-
nifier or a stereomicroscope. The microdissected samples
were collected in airtight plastic (Eppendorf) tubes and
stored at -80 C until further use. The temperature of
brain sections and the microdissected samples was kept
under 0 C during the whole procedure.
Fig. 7 The selective SUCLA2 mRNA expression in neurons based on
double labeling with in situ hybridization histochemistry for SUCLA2
and neuronal or glial markers. The distribution of Nissl-labeled cells
(a) and S100-immunoreactive astrocytes (b) is shown in the human
temporal cortex. The tiny autoradiography grains of the in situ
hybridization signal are not visible at this low magnification. High-
magnification pictures demonstrate the location of autoradiography
grains representing SUCLA2 mRNA in relation to Nissl-labeled cells
(c), and S100-immunoreactive astrocytes (d). Black arrowheads
indicate double-labeled cells. Based on the larger size and fainter
Nissl labeling, these cells are neurons. Above these cells, the number
of autoradiography grains is more than four. In contrast, the darker,
smaller and circular-shaped glial cells indicated by white arrowheads
in c are not labeled for SUCLA2 mRNA. Also, mRNA expression of
SUCLA2 is absent in S100-immunoreactive astrocytes (white arrow-
heads) in d. Scale bars 500 lm for a, b and 50 lm for c, d
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Mouse brains
Wild type C57BL/6 mice were obtained from Jackson Lab-
oratory (JAX Mice repository, Bar Harbor, Maine, USA).
The animals used in our study were of either sex and 5 and
6 months of age. Mice were housed in a room maintained at
20–22 C on a 12-h light–dark cycle with food and water
available ad libitum. All experiments were approved by the
Animal Care and Use Committee of the Semmelweis Uni-
versity (Egyetemi A´llatkı´se´rleti Bizottsa´g). Mice were killed
by cervical dislocation and their brains were removed and
kept at -80 C until further manipulations.
Cell cultures
Fibroblast cultures from skin biopsies from the patient with
no SUCLA2 expression and control subjects were pre-
pared. Cells were grown on poly-L-ornithine coated 25 mm
round glass coverslips for 5–7 days, at a density of
approximately 8 9 105 cells/coverslip in RPMI 1640
medium (GIBCO, Life technologies, Carlsbad, CA, USA)
supplemented with 10 % fetal bovine serum and 2 mM
glutamine and kept at 37 C in 5 % CO2. The medium was
also supplemented with penicillin, streptomycin and
amphotericin (item A5955, Sigma-Aldrich St. Louis, MO,
USA). HEK293 cells were grown on poly-L-ornithine
coated 25 mm round glass coverslips for 1–2 days, at a
density of approximately 5 9 105 cells/coverslip in
DMEM (GIBCO) plus glutamine plus 10 % fetal calf
serum and 1 % streptomycin–penicillin.
Tissue collection for immunolabeling
For immunocytochemistry, brains were cut into 5–10 mm
thick coronal slices and immersion fixed in 4 % parafor-
maldehyde in 0.1 M phosphate-buffered saline (PBS) for
3–5 days. Subsequently, the blocks were transferred to
PBS containing 0.1 % sodium azide for 2 days to remove
excess paraformaldehyde. Then the blocks were placed in
PBS containing 20 % sucrose for 2 days for cryoprotec-
tion, after which the blocks were frozen and cut into 50 lm
thick serial coronal sections on a sliding microtome. Sec-
tions were collected in PBS containing 0.1 % sodium azide
and stored at 4 C until further processing.
DAB immunolabeling of brain sections
Every fifth free-floating brain section of human temporal
and frontal cortical blocks was immunostained for SU-
CLA2 and SUCLG2. The antibodies (at dilutions 1:80,
1:320, 1:1,280, 1:5,120) were applied for 48 h at room
temperature, followed by incubation of the sections in
biotinylated anti-rabbit secondary antibody (1:1,000 dilu-
tion, Vector Laboratories, Burlingame, CA) and then in
Fig. 8 Immunoreactivities of the substrate-specific b subunit
encoded by either SUCLA2 or SUCLG2 in tissue homogenates.
a MB signifies mouse brain (whole brain homogenates from four
different animals 1, 2, 3 and 4). All other alphanumeric titles signify
human brain samples obtained from regions as indicated in the panels.
b Immunoreactivity of the substrate-specific b subunit encoded by
SUCLA2 in human fibroblasts from a healthy donor and a patient
with a complete deletion of SUCLA2. c Immunoreactivities of the
substrate-specific b subunit encoded by either SUCLA2 or SUCLG2
in human temporal cortex samples from control subjects versus those
that suffered from diabetes mellitus. For all lanes of all panels,
immunoreactivity of b-actin was used as a loading control
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avidin–biotin-peroxidase complex (1:500, Vector Labora-
tories) for 2 h. Subsequently, the labeling was visualized
by incubation in 0.02 % 3,3-diaminobenzidine (DAB;
Sigma), 0.08 % nickel (II) sulfate and 0.001 % hydrogen
peroxide in PBS, pH 7.4 for 5 min. Sections were mounted,
dehydrated and coverslipped with Cytoseal 60 (Stephens
Scientific, Riverdale, NJ, USA).
Double labeling of SUCLA2 in brains sections
SUCLA2 was immunolabeled as for single labeling using
1:1,000 dilution except for the visualization, which was
performed with fluorescein isothiocyanate (FITC)-tyramide
(1:8,000) and H2O2 in 100 mM Trizma buffer (pH 8.0
adjusted with HCl) for 6 min. Subsequently, sections were
placed in mouse anti-subunit d of the F0–F1 ATP synthase
(1:500), or mouse anti-S100, a marker of glial cells (1:500,
Millipore, Cat. No. MAB079-1) for 48 h at room temper-
ature. The sections were then incubated in Alexa 594
donkey anti-mouse secondary antibody (1:500, Molecular
Probes, Eugene, OR) for 2 h and washed. For the double
labeling with Nissl staining, the sections were incubated in
‘Neurotrace’ red fluorescent Nissl stain (Molecular Probes)
diluted to 1:30 for 2 h, and washed in PBS overnight. For
double labeling with glial fibrillary acidic protein (GFAP),
a marker of glial cells, the sections were first incubated in
mouse anti-GFAP (1:300, Santa Cruz Biotechnology,
Delaware, CA, USA; Cat. No. sc-33673) and developed
with FITC-tyramide amplification immunofluorescence as
described above for SUCLA2. Then, the anti-SUCLA2
antiserum was used at a 1:350 dilution and visualized by
Alexa 594 donkey anti-rabbit secondary antibody (1:500,
Molecular Probes). Finally, all sections with fluorescent
labels were mounted on positively charged slides (Super-
frost Plus, Fisher Scientific, Pittsburgh, PA) and covers-
lipped in antifade medium (Prolong Antifade Kit,
Molecular Probes).
Immunocytochemistry of cell cultures
Fibroblasts or HEK293 cell cultures were first treated with
1 lM Mitotracker Orange (MTO) for 5 min in their culture
media, at 37 C in 5 % CO2. Subsequent immunocyto-
chemistry of the cultures was performed by fixing the cells
with 4 % paraformaldehyde in PBS for 20 min, followed
by permeabilization by 0.1 % TX-100 (in PBS) for 10 min
and several washing steps in between with PBS at room
temperature. Cultures were treated with 10 % donkey
serum overnight at 4 C followed by bathing in 1 % don-
key serum and 1 lg/ml anti-SUCLA2 (Proteintech Europe
Ltd, Manchester, UK, Cat. No. #12627-1-AP) or 1 lg/ml
anti-SUCLG2 (Abcam, Cambridge, UK, Cat. No.
#ab96172) for 1 h at room temperature. Cells were
subsequently decorated using the appropriate Cy2- or
Alexa 488-linked secondary antibody (1:4,000, donkey
anti-rabbit, Jackson Immunochemicals Europe Ltd, Cam-
bridgeshire, UK) in the presence of 1 % donkey serum.
Western blotting
Cultured fibroblasts were harvested by trypsinization.
Frozen brain samples were thawn on ice in the presence of
radioimmunoprecipitation assay buffer and a protease
cocktail inhibitor containing: 0.5 mM 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride, 150 nM Aproti-
nin, 1 lM E-64, 0.5 mM EDTA disodium, and 1 lM
Leupeptin, and homogenized with a Teflon pestle. The
suspensions were centrifuged once at 10,000g for 10 min,
and the proteins present in the supernatants were separated
by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE). Separated proteins were transferred to a
methanol-activated polyvinylidene difluoride membrane.
Immunoblotting was performed as recommended by the
manufacturers of the antibodies. Rabbit polyclonals anti-
SUCLG2 (Abcam, Cambridge, UK), and anti-SUCLA2
primary antibodies were used at concentrations of 1 lg/ml,
and rabbit polyclonal anti-b actin (Abcam) at 0.1 lg/ml.
Immunoreactivity was detected using the appropriate per-
oxidase-linked secondary antibody (1:4,000, donkey anti-
rabbit, Jackson Immunochemicals Europe Ltd, Cam-
bridgeshire, UK) and enhanced chemiluminescence detec-
tion reagent (ECL system; Amersham Biosciences GE
Healthcare Europe GmbH, Vienna, Austria).
RT-PCR
RNA was isolated from surgically dissected human tem-
poral cortex and cultured human fibroblasts. The surgical
brain tissue sample was quickly frozen on dry ice and kept
at -80 C until RNA isolation. The fibroblasts were cen-
trifuged and resuspended in PBS immediately before RNA
isolation. Both the brain surgical samples and the fibro-
blasts were homogenized in TrizolR Reagent (Invitrogen,
Carlsbad, CA, USA) and RNA was isolated according to
the manufacturer’s instructions. After diluting RNA to
1 lg/ll, it was treated with Amplification Grade DNase I
(Invitrogen) and cDNA was synthesized with a SuperScript
II reverse transcriptase kit (Invitrogen) according to the
manufacturer’s instructions. After tenfold dilution, 2.5 ll
of the resulting cDNA was used as template in PCR
reactions performed with iTaq DNA polymerase (Bio-Rad
Laboratories, Hercules, CA, USA) in total volumes of
12.5 ll under the following conditions: 95 C for 3 min,
followed by 35 cycles of 95 C for 0.5 min, 60 C for
0.5 min and 72 C for 1 min. Primers were used at 300 nM
final concentration for SUCLA2 (primer pair A:
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CCAGCCAACTTCCTTGATGT and TCAGTGCCTTAG
CATCATCG, primer pair B: TGCTGAGTCTCCTGAAG
CAA and TCATCTTCCTGGGTCCAGTC, primer pair C:
GCAGCAGAAAACATGGTCAA and CCATCGAGGCC
AATGTAGTT), and SUCLG2 (primer pair A: GAAGCTC
TCGAGGCTGCTAA and GTCCATCAGAATTGCCAG
GT, primer pair B: CCCTTTGGTGAAACTCCAGA and
AATGATGGCACAGTTGACGA, primer pair C: GGTCC
CAGGCAGTTCAATTA and TATCCAAGGCTTCAGCA
ACC, primer pair D: CATTGCCTGCTTTGTGAATG and
AATGATGGCACAGTTGACGA). The calculated lengths
of the PCR products are 235, 309, and 242 base pairs (bp)
for human SUCLA2 (1,081–1,315, 645–953, and 763–
1,004 bp of GenBank accession number NM_003850.2),
and 279, 387, 366, and 211 bp for human SUCLG2
(227–505, 758–1,144, 105–470, and 934–1,144 bp of
GenBank accession number NM_001177599.1). The
primers were chosen to generate probes that recognize all
known RNA species for the particular gene. The resulting
PCR products are intron-spanning, to detect potential
genomic DNA contamination by its larger size. PCR
products were run on gel and pictures were taken by a
digital camera. Images were cropped and contrast was
adjusted using the ‘‘levels’’ command in Adobe Photoshop
CS 8.0.
Preparation of in situ hybridization probes
The PCR products using primer pairs A and B for both
SUCLA2 and SUCLG2 were purified from gel to obtain
non-overlapping probes to demonstrate specific labeling.
The purified PCR products were inserted into TOPO TA
cloning vectors (Invitrogen) and transformed chemically
into competent bacteria according to the manufacturer’s
instructions. Plasmids were purified from 5 to 7 colonies
and applied as templates in PCR reactions with the specific
primer pairs to select plasmids containing specific inserts.
A positive plasmid for each probe was applied as template
in PCR reactions, using primer pairs specific for the probe
and also containing T7 RNA polymerase recognition site
(GTAATACGACTCACTATAGGGCGAATTGGGTA)
added to the reverse primers. Finally, the identities of the
cDNA probes were verified by sequencing them with T7
primers.
In situ hybridization histochemistry
Surgically dissected temporal cortical brain samples from
two patients were quickly frozen on dry ice, and kept at
-80 C. Serial coronal sections (12 lm thick) were cut using
a cryostat, mounted on positively charged slides (Superfrost
Plus), dried, and stored at -80 C until use. [35S] UTP-
labeled riboprobes were generated from the DNA probes
containing T7 RNA polymerase recognition sites using a
MAXIscript transcription kit (Ambion, Austin, TX, USA).
The preparation of tissue was performed using mRNA
locator Kit (Ambion), according to the manufacturer’s
instructions. For hybridization, we used 80 ll hybridization
buffer (mRNA locator Kit; Ambion) and labeled probes of
1 million DPM activity per slide. Washing procedures
included a 30 min incubation in RNase A followed by
decreasing concentrations of sodium-citrate buffer (pH 7.4)
at room temperature and subsequently at 65 C. Following
successive dehydration and drying, the slides were dipped
in ‘NTB’ nuclear track emulsion (Eastman Kodak,
Rochester, NY, USA) and stored at 4 C for 3 weeks. Then
the slides were developed and fixed with Kodak Dektol
developer and Kodak fixer, respectively, counterstained
with Giemsa, and coverslipped with Cytoseal 60 (Stephens
Scientific). A cell was considered to express SUCLA2 or
SUCLG2 if the number of autoradiography grains accu-
mulated in a seemingly Gaussian distribution around a
center was at least three times higher than the background
level in an area corresponding to an average cell size (a
circle with a diameter of 25 lm) in the same section. The
background typically consisted of 1–3 grains per cell.
Combination of in situ hybridization histochemistry
with Nissl staining
Slide attached sections of fresh temporal cortical brain
tissue were first processed for in situ hybridization, as
described above. After development, the sections were
stained with 0.1 % cresyl-violet dissolved in PBS, and then
immersed in 96 % ethanol containing 0.01 % acetic acid.
Alternatively, the sections were incubated in ‘Neurotrace’
red fluorescent Nissl stain (Molecular Probes,) diluted to
1:30 for 2 h, washed in PBS overnight, and coverslipped in
antifade medium (Prolong Antifade Kit, Molecular
Probes). A cell was considered glial if it was dark labeled,
and had a small diameter round-shape appearance. In turn,
neurons exhibited less intense labeling, were larger and
their shape was less regularly rounded. A cell was con-
sidered SUCLA2-expressing if it met the criteria described
above for single label in situ hybridization histochemistry.
A SUCLA2-expressing cell was considered Nissl-labeled if
at least 70 % of the area of the circle containing the
accumulation of autoradiography grains contained Nissl
labeling, and the center of the autoradiography grains was
within the Nissl labeling.
Combination of in situ hybridization histochemistry
with S100 immunohistochemistry
Slide attached sections (20 lm thick) of fixed temporal
cortical brain brains were first processed for in situ
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hybridization, as described above. Thus, tightly bound
RNA–RNA pairs were already formed by the time immu-
nohistochemistry was performed, immediately before dip-
ping the slides into autoradiographic emulsion. In addition,
the solutions used for perfusion and immunohistochemistry
were prepared with DAPC-treated RNAse-free water,
which ensured that the labeling intensity of the in situ
hybridization histochemistry did not decrease significantly.
The immunolabeling protocol for S100 was the same as
that described above for double labeling immunohisto-
chemistry. Immunoreactivity was visualized using DAB
reactions, after which the in situ hybridization procedure
was continued by dipping the slides into the emulsion.
Each double labeling experiment included controls, which
was carried out through the double labeling procedure
without application of radioactive in situ hybridization
probes. These controls demonstrated that the DAB signal
did not induce an autoradiography signal. A SUCLA2-
expressing cell was considered S100-immunopositive if at
least 70 % of the area of the circle containing the accu-
mulation of autoradiography grains contained immunore-
activity for S100 and the center of the autoradiography
grains was within the immunolabeled cell.
Image processing
The sections were examined using an Olympus BX60
light microscope equipped with bright-field, dark-field and
fluorescence. Images were captured at 2,048 9 2,048
pixel resolution with a SPOT Xplorer digital CCD camera
(Diagnostic Instruments, Sterling Heights, MI, USA)
using a 49 objective for dark-field images, and 4–409
objectives for bright-field and fluorescent images. Fluo-
rescent sections were also evaluated using a Bio-Rad
2100 Rainbow Confocal System (Bio-Rad Laboratories,
Inc, CA, USA). The contrast and sharpness of the images
were adjusted using the ‘‘levels’’ and ‘‘sharpness’’ com-
mands in Adobe Photoshop CS 8.0. Full resolution was
maintained until the photomicrographs were finally crop-
ped at which point the images were adjusted to a reso-
lution of 300 dpi.
Analysis of double immunolabeling
Three 1 9 1 mm areas of double-labeled remote sections
from each brain were randomly selected. The total number
of SUCLA2-positive neurons with an identifiable cell
nucleus and the number of double-labeled cells was
counted using a 209 objective of an Olympus BX60 light
microscope equipped with fluorescent epi-illumination and
a filter allowing for visualization of both green and red
colors. Subsequently, the number of single labeled cells
was also calculated in the area.
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